Antengene Showcases Promising Clinical Data for ATG-022, ATG-037, and ATG-101 at 2025 R&D Day
Antengene Corporation Ltd. is presenting clinical data and future development plans for its investigational programs ATG-022, ATG-037, and ATG-101 at the 2025 R&D Day event. The company will also update on the ATG-125 program and AnTenGager™ T-cell engager technology, along with preclinical programs. The event is scheduled for today, with results to be shared during the session. This information was originally published by Antengene via PR Newswire on November 20, 2025.
Antengene Corporation Ltd. announced that it will present the latest clinical data and future development plans for three of its mid- to late-stage investigational programs-ATG-022 (a CLDN18.2 antibody-drug conjugate), ATG-037 (an oral CD73 small molecule inhibitor), and ATG-101 (a PD-L1/4-1BB bispecific antibody)-at its 2025 R&D Day event. The company also plans to share updates on its ATG-125 (a B7H3 x PD-L1 bispecific ADC) program and the AnTenGager™ T-cell engager (TCE) technology platform, as well as provide information on several preclinical programs. The event is scheduled to take place today, with results and progress to be presented during the session. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Antengene Corporation Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN28821) on November 20, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
